FSD Pharma (Canada)

Recent papers from FSD Pharma (Canada)

1. Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian PracticeDermatology and Therapy · 2026
2. DMG-41. Development of Brain-Penetrant ALK2 Inhibitors for Diffuse Intrinsic Pontine Glioma (DIPG): An Open Science Approach.Neuro-Oncology Pediatrics · 2025
3. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN ChinaDiabetes Obesity and Metabolism · 2023
4. Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of a Fully Liquid Combination Diphtheria–Tetanus Toxoid–Five-Component Acellular Pertussis (DTaP₅), Inactivated Poliovirus (IPV), and Haemophilus influenzae Type b (Hib) Vaccine Compared with a DTaP₃-IPV/Hib Vaccine Administered at 3, 5, and 12 Months of AgeClinical and Vaccine Immunology · 2013
5. Angiotensin II Receptor Blockers in Pregnancy: A Case Report and Systematic Review of the LiteratureHypertension in Pregnancy · 2007